October is Breast Cancer Awareness Month NEW STUDY CONFIRMS EVEN MORE WOMEN WITH BREAST CANCER CAN SKIP CHEMOTHERAPY
18 de oct. de 2021 ·
14m 34s
Regístrate gratis
Escucha este episodio y muchos más. ¡Disfruta de los mejores podcasts en Spreaker!
Descarga y escucha en cualquier lugar
Descarga tus episodios favoritos y disfrútalos, ¡dondequiera que estés! Regístrate o inicia sesión ahora para acceder a la escucha sin conexión.
Descripción
New research expands the number of women with a common type of early stage breast cancer who can skip chemotherapy and safely be treated with hormone-blocking therapies alone – even...
mostra más
New research expands the number of women with a common type of early stage breast cancer who can skip chemotherapy and safely be treated with hormone-blocking therapies alone – even if their cancer has spread to some of their lymph nodes.[1] However, women whose tumors have spread to their lymph nodes are often at higher risk of worse outcomes, with the majority receiving chemotherapy.[2]
Results from the RxPONDER study, one of the largest clinical trials in hormone receptor-positive, HER2 negative early breast cancer, were presented at the San Antonio Breast Cancer Symposium in late 2020.1
Based on these new findings, postmenopausal women whose cancer has spread to between one and three lymph nodes can avoid the side effects associated with chemotherapy if their Oncotype DX Breast Recurrence Score® result, a genomic test which predicts chemotherapy benefit and risk of cancer recurrence, is between...
for video and more info go to https://goodnewsplanet.com/october-is-breast-cancer-awareness-month-new-study-confirms-even-more-women-with-breast-cancer-can-skip-chemotherapy/
##breast #cancer #chemotherapy #therapies #hormone #blocking #lymph #nodes #rxponder #menopausal #effects #oncotype #dx #recurrence #genomic #benefit #risk #exact
mostra menos
Results from the RxPONDER study, one of the largest clinical trials in hormone receptor-positive, HER2 negative early breast cancer, were presented at the San Antonio Breast Cancer Symposium in late 2020.1
Based on these new findings, postmenopausal women whose cancer has spread to between one and three lymph nodes can avoid the side effects associated with chemotherapy if their Oncotype DX Breast Recurrence Score® result, a genomic test which predicts chemotherapy benefit and risk of cancer recurrence, is between...
for video and more info go to https://goodnewsplanet.com/october-is-breast-cancer-awareness-month-new-study-confirms-even-more-women-with-breast-cancer-can-skip-chemotherapy/
##breast #cancer #chemotherapy #therapies #hormone #blocking #lymph #nodes #rxponder #menopausal #effects #oncotype #dx #recurrence #genomic #benefit #risk #exact
Información
| Autor | Paul Sladkus |
| Página web | - |
| Etiquetas |
Copyright 2024 - Spreaker Inc. an iHeartMedia Company
